138 related articles for article (PubMed ID: 30911782)
1. Use of antiosteoporotic medication in the Danish ROSE population-based screening study.
Høiberg MP; Rubin KH; Holmberg T; Rothmann MJ; Möller S; Gram J; Bech M; Brixen K; Hermann AP
Osteoporos Int; 2019 Jun; 30(6):1223-1233. PubMed ID: 30911782
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study.
Rubin KH; Rothmann MJ; Holmberg T; Høiberg M; Möller S; Barkmann R; Glüer CC; Hermann AP; Bech M; Gram J; Brixen K
Osteoporos Int; 2018 Mar; 29(3):567-578. PubMed ID: 29218381
[TBL] [Abstract][Full Text] [Related]
3. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
[TBL] [Abstract][Full Text] [Related]
4. Non-participation in systematic screening for osteoporosis-the ROSE trial.
Rothmann MJ; Möller S; Holmberg T; Højberg M; Gram J; Bech M; Brixen K; Hermann AP; Glüer CC; Barkmann R; Rubin KH
Osteoporos Int; 2017 Dec; 28(12):3389-3399. PubMed ID: 28875257
[TBL] [Abstract][Full Text] [Related]
5. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.
Hadji P; Claus V; Ziller V; Intorcia M; Kostev K; Steinle T
Osteoporos Int; 2012 Jan; 23(1):223-31. PubMed ID: 21308365
[TBL] [Abstract][Full Text] [Related]
6. Self-perception of fracture risk: what can it tell us?
Litwic AE; Compston JE; Wyman A; Siris ES; Gehlbach SH; Adachi JD; Chapurlat R; Díez-Pérez A; LaCroix AZ; Nieves JW; Netelenbos JC; Pfeilschifter J; Rossini M; Roux C; Saag KG; Silverman S; Watts NB; Greenspan SL; March L; Gregson CL; Cooper C; Dennison EM;
Osteoporos Int; 2017 Dec; 28(12):3495-3500. PubMed ID: 28861636
[TBL] [Abstract][Full Text] [Related]
7. The impact of GI events on persistence and adherence to osteoporosis treatment: 3-, 6-, and 12-month findings in the MUSIC-OS study.
Modi A; Sen S; Adachi JD; Adami S; Cortet B; Cooper AL; Geusens P; Mellström D; Weaver JP; van den Bergh JP; Keown P; Sajjan S
Osteoporos Int; 2018 Feb; 29(2):329-337. PubMed ID: 29110061
[TBL] [Abstract][Full Text] [Related]
8. Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study.
Silverman SL; Siris E; Belazi D; Recknor C; Papaioannou A; Brown JP; Gold DT; Lewiecki EM; Quinn G; Balasubramanian A; Yue S; Stolshek B; Kendler DL
Arch Osteoporos; 2018 Aug; 13(1):85. PubMed ID: 30088189
[TBL] [Abstract][Full Text] [Related]
9. Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis.
Liu J; Guo H; Rai P; Pinto L; Barron R
Osteoporos Int; 2018 Nov; 29(11):2409-2417. PubMed ID: 30022254
[TBL] [Abstract][Full Text] [Related]
10. How the knowledge of fracture risk might influence adherence to oral therapy of osteoporosis in Italy: the ADEOST study.
Gonnelli S; Caffarelli C; Rossi S; Di Munno O; Malavolta N; Isaia G; Muratore M; D'Avola G; Gatto S; Minisola G; Nuti R
Aging Clin Exp Res; 2016 Jun; 28(3):459-68. PubMed ID: 26873817
[TBL] [Abstract][Full Text] [Related]
11. Examining the treatment gap and risk of subsequent fractures among females with a fragility fracture in the US Medicare population.
Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
Osteoporos Int; 2017 Aug; 28(8):2485-2494. PubMed ID: 28536737
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of osteoporotic fracture risk factors and antiosteoporotic treatments in the Valencia region, Spain. The baseline characteristics of the ESOSVAL cohort.
Sanfélix-Genovés J; Sanfélix-Gimeno G; Peiró S; Hurtado I; Fluixà C; Fuertes A; Campos JC; Giner V; Baixauli C
Osteoporos Int; 2013 Mar; 24(3):1045-55. PubMed ID: 22618269
[TBL] [Abstract][Full Text] [Related]
13. Increased treatment persistence and its determinants in women with osteoporosis with prior fracture compared to those without fracture.
Jacob L; Dreher M; Kostev K; Hadji P
Osteoporos Int; 2016 Mar; 27(3):963-969. PubMed ID: 26519418
[TBL] [Abstract][Full Text] [Related]
14. Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap.
Ban JK; Hao BB; McCarthy L; Guilcher SJT; Cadarette SM
Osteoporos Int; 2019 Sep; 30(9):1865-1872. PubMed ID: 31317248
[TBL] [Abstract][Full Text] [Related]
15. US Preventative Services Task Force FRAX threshold has a low sensitivity to detect osteoporosis in women ages 50-64 years.
Bansal S; Pecina JL; Merry SP; Kennel KA; Maxson J; Quigg S; Thacher TD
Osteoporos Int; 2015 Apr; 26(4):1429-33. PubMed ID: 25614141
[TBL] [Abstract][Full Text] [Related]
16. Socioeconomic status and risk of osteoporotic fractures and the use of DXA scans: data from the Danish population-based ROSE study.
Holmberg T; Möller S; Rothmann MJ; Gram J; Herman AP; Brixen K; Tolstrup JS; Høiberg M; Bech M; Rubin KH
Osteoporos Int; 2019 Feb; 30(2):343-353. PubMed ID: 30465216
[TBL] [Abstract][Full Text] [Related]
17. A dedicated Fracture Liaison Service telephone program and use of bone turnover markers for evaluating 1-year persistence with oral bisphosphonates.
van den Berg P; van Haard PMM; van der Veer E; Geusens PP; van den Bergh JP; Schweitzer DH
Osteoporos Int; 2018 Apr; 29(4):813-824. PubMed ID: 29260291
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium.
Fahrleitner-Pammer A; Papaioannou N; Gielen E; Feudjo Tepie M; Toffis C; Frieling I; Geusens P; Makras P; Boschitsch E; Callens J; Anastasilakis AD; Niedhart C; Resch H; Kalouche-Khalil L; Hadji P
Arch Osteoporos; 2017 Dec; 12(1):58. PubMed ID: 28643265
[TBL] [Abstract][Full Text] [Related]
19. Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial.
Montori VM; Shah ND; Pencille LJ; Branda ME; Van Houten HK; Swiglo BA; Kesman RL; Tulledge-Scheitel SM; Jaeger TM; Johnson RE; Bartel GA; Melton LJ; Wermers RA
Am J Med; 2011 Jun; 124(6):549-56. PubMed ID: 21605732
[TBL] [Abstract][Full Text] [Related]
20. Persistence and compliance to osteoporosis therapy in a fracture liaison service: a prospective cohort study.
Senay A; Fernandes JC; Delisle J; Morin SN; Perreault S
Arch Osteoporos; 2019 Aug; 14(1):87. PubMed ID: 31375983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
